NPY and cancer: The efficiency of cancer treatment might also increase β‐blockers and drugs reducing the effect of the norepinephrine co‐transmitter, neuropeptide Y. Recent studies have shown that propranolol reduced resistance and increased sensitivity to chemotherapy in patients with sarcoma or ovarian cancer149, 150 and inhibited cellular and molecular pathways associated with adverse outcomes in hematopoietic cell transplant recipients.151